Efficacy and safety of albumin for the treatment of hepatic encephalopathy: an updated systematic review and meta-analysis of randomized controlled trials
Authors:
- Farhan Mbbs MurtazaFMFarhan Mbbs Murtaza
- Midhun MathewMMMidhun Mathew
- Oluwaseun FagbamilaOFOluwaseun Fagbamila
- Sachin Mbbs SubramaniSSSachin Mbbs Subramani
- Simran Mbbs NimalSNSimran Mbbs Nimal
- Veeramachaneni Naga Mbbs NyshitaVNVeeramachaneni Naga Mbbs Nyshita
- Vishnu Mbbs PriyaVPVishnu Mbbs Priya
- Abu Talha Mbbs SanyASAbu Talha Mbbs Sany
- Yamanth Mbbs KumarYKYamanth Mbbs Kumar
- Laura Mbbs CicaniLCLaura Mbbs Cicani
- Muhammad Mbbs EhsanMEMuhammad Mbbs Ehsan
- Kamal Mbbs KandelKKKamal Mbbs Kandel
Open Access
- 24 April 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (6) , 3416-3422
Abstract
Background: Albumin acts as a scavenger of reactive oxygen species and an inhibitor of inflammatory processes that underlie hepatic encephalopathy (HE). However, the role of albumin in hepatic encephalopathy is not well-established. The authors performed this meta-analysis to evaluate the efficacy and safety of albumin in the management of hepatic encephalopathy. Methods: The authors carried out an extensive search across multiple databases, including MEDLINE (via PubMed), Embase, CENTRAL, and various trial registries, to identify randomized controlled trials (RCTs) evaluating the impact of albumin administration in HE. The authors used a random-effects model for analyses and presented dichotomous outcomes and continuous outcomes as relative risk and mean difference, along with corresponding 95% CIs, respectively. Heterogeneity was assessed using both the I2 index and χ2 test. Results: Our meta-analysis included 4 RCTs involving 306 patients. Our primary outcomes, mortality, and persistence of HE were reported by all four studies. Albumin was found to significantly decrease mortality in patients with HE [risk ratio (RR) 0.52, 95% CI 0.32–0.83; I2 =0%]. Persistence of HE was found to be comparable between the two groups (RR 0.83, 95% CI 0.68–1.00; I2 =24%). There was no significant difference between the albumin and control groups regarding length of hospital stay (MD −1.55, 95% CI −3.5 to 0.14; I2 =41%), adverse events (RR 1.00, 95% CI 0.87–1.16; I2 =0%), and severe adverse events (RR 0.89, 95% CI 0.59–1.35). Conclusion: Albumin administration in patients with hepatic encephalopathy decreases mortality but does not significantly impact the persistence of HE. Further high-quality, large-scale randomized controlled trials are needed to provide conclusive evidence.Keywords
This publication has 21 references indexed in Scilit:
- Hepatic Encephalopathy: Current and Emerging Treatment ModalitiesClinical Gastroenterology and Hepatology, 2022
- Albumin in the management of hepatic encephalopathy: A systematic review and meta-analysisAnnals of Hepatology, 2021
- Increasing Burden of Hepatic Encephalopathy Among Hospitalized Adults: An Analysis of the 2010–2014 National Inpatient SampleDigestive Diseases and Sciences, 2019
- Hepatic Encephalopathy Is Associated With Mortality in Patients With Cirrhosis Independent of Other Extrahepatic Organ FailuresClinical Gastroenterology and Hepatology, 2017
- Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the LiverHepatology, 2014
- Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanismsHepatology, 2012
- Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathyMetabolic Brain Disease, 2011
- Alterations of Blood Brain Barrier Function in Hyperammonemia: An OverviewNeurotoxicity Research, 2011
- Advances in the Evaluation and Management of Minimal Hepatic EncephalopathyCurrent Gastroenterology Reports, 2010
- Ammonia: Key factor in the pathogenesis of hepatic encephalopathyNeurochemical Pathology, 1987